Cannabinoid Encyclopedia

Focused research review

Minor cannabinoids: what the research says

Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?

Updated July 2026 36 research sources Human research included

The short answer

What is the bottom line?

Research has examined Minor cannabinoids. This page brings together 14 human-study sources, 12 research reviews, and 4 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Minor cannabinoids.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Minor cannabinoids covers Safety, adverse-event, impairment, or formulation-specific concerns; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Minor cannabinoids

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Safety, adverse-event, impairment, or formulation-specific concerns

This part of the literature focuses on Safety, adverse-event, impairment, or formulation-specific concerns. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

14 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

12 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

4 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 6 of 36 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on Minor cannabinoids is not one kind of study. This source set includes 7 clinical studies in people, 7 narrative or expert reviews, 5 systematic reviews or meta-analyses, and 3 animal studies. 3

The recorded populations or models include people or patients (17 sources), pediatric, adolescent, or developmental context (5 sources), and animal models (4 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is safety, adverse-event, impairment, or formulation-specific concerns (36 sources). Closely related outcome names can still describe different measurements. 5

The Minor cannabinoids source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics.

On this page, this source examines CBG and safety, adverse-event, impairment, or formulation-specific concerns. 1

Study type
systematic review or meta-analysis
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
evidence still limited

narrative or expert review

Pharmacologic treatment of fibromyalgia: an update.

On this page, this source examines Cannabinoids and safety, adverse-event, impairment, or formulation-specific concerns. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
evidence still limited

human research

Adverse events associated with medical cannabis reported within a centralized call center.

On this page, this source examines Cannabinoids and safety, adverse-event, impairment, or formulation-specific concerns. 3

Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
human research

cell or laboratory study

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.

On this page, this source examines CBG and safety, adverse-event, impairment, or formulation-specific concerns. 4

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
mechanism-focused research

animal study

Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents.

On this page, this source examines CBC and safety, adverse-event, impairment, or formulation-specific concerns. 5

Study type
animal study
Population or model
animal models
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns
Evidence stage
preclinical research

Safety and limits

What should readers keep in mind?

Research on Minor cannabinoids should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Which safety, adverse-event, or impairment evidence exists for less-studied cannabinoids and commercial formulations?

Relevant research is collected here. The source set includes human research as well as earlier-stage studies. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. systematic review or meta-analysis; evidence still limited PubMed 38229238 DOI 10.1002/dta.3628
  2. 2
    Pharmacologic treatment of fibromyalgia: an update. narrative or expert review; evidence still limited PubMed 41142233 DOI 10.3389/fphar.2025.1651181
  3. 3
    Adverse events associated with medical cannabis reported within a centralized call center. human research PubMed 42158949 DOI 10.3389/fphar.2026.1792520
  4. 4
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research PubMed 39596290 DOI 10.3390/ijms252212224
  5. 5
    Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. animal study; preclinical research PubMed 40580638 DOI 10.1016/j.ejmech.2025.117888
  6. 6
    Cannabis-based medicines for chronic neuropathic pain in adults. systematic review or meta-analysis; evidence still limited PubMed 41548880 DOI 10.1002/14651858.cd012182.pub3
  7. 7
    Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. systematic review or meta-analysis; evidence still limited PubMed 39805119 DOI 10.1097/wnf.0000000000000619
  8. 8
    Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. systematic review or meta-analysis; evidence still limited PubMed 38868665 DOI 10.3389/fphar.2024.1282831
  9. 9
    The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. systematic review or meta-analysis; evidence still limited PubMed 21845389 DOI 10.1007/s00213-011-2417-y
  10. 10
    A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. clinical study in people; evidence still limited PubMed 31802404 DOI 10.1007/s40262-019-00841-6
  11. 11
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. clinical study in people; evidence still limited PubMed 30374683 DOI 10.1007/s40263-018-0578-5
  12. 12
    A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). clinical study in people; human research PubMed 37947792 DOI 10.1080/15502783.2023.2280113
See all 36 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Pharmacologic treatment of fibromyalgia: an update. narrative or expert review; evidence still limited / 1 linked research note PubMed 41142233
  2. The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 21845389
  3. Cannabis-based medicines for chronic neuropathic pain in adults. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 41548880
  4. Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. evidence still limited / 1 linked research note PubMed 40708053
  5. Adverse events associated with medical cannabis reported within a centralized call center. human research / 1 linked research note PubMed 42158949
  6. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research / 1 linked research note PubMed 41698831
  7. Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. case report or case series; evidence still limited / 1 linked research note PubMed 37217977
  8. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 38868665
  9. Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 39805119
  10. Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. evidence still limited / 1 linked research note PubMed 38176407
  11. Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. case report or case series; evidence still limited / 1 linked research note PubMed 36742440
  12. Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. case report or case series; human research / 1 linked research note PubMed 36941718
  13. Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. human research / 1 linked research note PubMed 38696245
  14. Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39596290
  15. Cannabinoids in clinical practice. narrative or expert review; evidence still limited / 1 linked research note PubMed 11152013
  16. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). clinical study in people; human research / 1 linked research note PubMed 37947792
  17. Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. narrative or expert review; evidence still limited / 1 linked research note PubMed 40206058
  18. Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 42163693
  19. Safety study of cannabidiol products in healthy dogs. clinical study in people; human research / 1 linked research note PubMed 38496308
  20. Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. human research / 1 linked research note PubMed 42057192
  21. Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39004335
  22. Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. clinical study in people; mechanism-focused research / 1 linked research note PubMed 41822224
  23. The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited / 1 linked research note PubMed 38777605
  24. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40872492
  25. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 37630401
  26. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. clinical study in people; human research / 1 linked research note PubMed 37162192
  27. A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 38229238
  28. Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. animal study; preclinical research / 1 linked research note PubMed 40580638
  29. Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. animal study; preclinical research / 1 linked research note PubMed 37721989
  30. CBD, a precursor of THC in e-cigarettes. evidence still limited / 1 linked research note PubMed 33903673
  31. The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research / 1 linked research note PubMed 36916438
  32. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. clinical study in people; evidence still limited / 1 linked research note PubMed 30374683
  33. Update on Cannabidiol in Drug-Resistant Epilepsy. narrative or expert review; evidence still limited / 1 linked research note PubMed 39585547
  34. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. clinical study in people; evidence still limited / 1 linked research note PubMed 31802404
  35. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. evidence still limited / 1 linked research note PubMed 33667843
  36. Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. evidence still limited / 1 linked research note PubMed 37593907